{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:02:04Z","timestamp":1792929724262,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32027802, 82372025, 82030049, 82394433, 82361148130, 82502424"],"award-info":[{"award-number":["32027802, 82372025, 82030049, 82394433, 82361148130, 82502424"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"Postdoctoral Science Foundation of China","doi-asserted-by":"crossref","award":["2023M743024"],"award-info":[{"award-number":["2023M743024"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Postdoctoral Fellowship Program of China Postdoctoral Science Foundation","award":["GZC20232302"],"award-info":[{"award-number":["GZC20232302"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["226202400059"],"award-info":[{"award-number":["226202400059"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07830-5","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:33:17Z","timestamp":1772847197000},"page":"4812-4823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The [18F]FDG PET\/CT for prognostic stratification in multiple myeloma: A systematic review and meta-analysis"],"prefix":"10.1007","volume":"53","author":[{"given":"Meiling","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4084-5150","authenticated-orcid":false,"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"7830_CR1","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Baz R, et al. Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21:1281\u2013301. https:\/\/doi.org\/10.6004\/jnccn.2023.0061.","journal-title":"J Natl Compr Canc Netw"},{"key":"7830_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327:464\u201377. https:\/\/doi.org\/10.1001\/jama.2022.0003.","journal-title":"JAMA"},{"key":"7830_CR3","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","volume":"109","author":"H Avet-Loiseau","year":"2007","unstructured":"Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the intergroupe francophone du my\u00e9lome. Blood. 2007;109:3489\u201395. https:\/\/doi.org\/10.1182\/blood-2006-08-040410.","journal-title":"Blood"},{"key":"7830_CR4","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1007\/s00330-018-5537-5","volume":"28","author":"A Kosmala","year":"2018","unstructured":"Kosmala A, Weng AM, Krauss B, Knop S, Bley TA, Petritsch B. Dual-energy CT of the bone marrow in multiple myeloma: diagnostic accuracy for quantitative differentiation of infiltration patterns. Eur Radiol. 2018;28:5083\u201390. https:\/\/doi.org\/10.1007\/s00330-018-5537-5.","journal-title":"Eur Radiol"},{"key":"7830_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (apollo): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:801\u201312. https:\/\/doi.org\/10.1016\/S1470-2045(21)00128-5.","journal-title":"Lancet Oncol"},{"key":"7830_CR6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(21)00135-5.","journal-title":"Lancet"},{"key":"7830_CR7","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863\u20139. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267.","journal-title":"J Clin Oncol"},{"key":"7830_CR8","doi-asserted-by":"publisher","first-page":"18442","DOI":"10.18632\/aging.203294","volume":"13","author":"L Liu","year":"2021","unstructured":"Liu L, Qu J, Dai Y, Qi T, Teng X, Li G, et al. An interactive nomogram based on clinical and molecular signatures to predict prognosis in multiple myeloma patients. Aging. 2021;13:18442\u201363. https:\/\/doi.org\/10.18632\/aging.203294.","journal-title":"Aging"},{"key":"7830_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/CBM-220451","volume":"38","author":"W Lu","year":"2023","unstructured":"Lu W, Xu S, Tan S, Lu L, Luo M, Xiao M. Comprehensive analysis and establishment of a prognostic model based on non-genetic predictors in multiple myeloma. Cancer Biomark. 2023;38:49\u201359. https:\/\/doi.org\/10.3233\/CBM-220451.","journal-title":"Cancer Biomark"},{"key":"7830_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","volume":"12","author":"P Hagen","year":"2022","unstructured":"Hagen P, Zhang J, Barton K. High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J. 2022;12:83. https:\/\/doi.org\/10.1038\/s41408-022-00679-5.","journal-title":"Blood Cancer J"},{"key":"7830_CR11","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.immuni.2021.07.002","volume":"54","author":"D Hofbauer","year":"2021","unstructured":"Hofbauer D, Mougiakakos D, Broggini L, Zaiss M, B\u00fcttner-Herold M, Bach C, et al. \u03b22-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression. Immunity. 2021;54:1772\u201387. https:\/\/doi.org\/10.1016\/j.immuni.2021.07.002.","journal-title":"Immunity"},{"key":"7830_CR12","doi-asserted-by":"publisher","first-page":"2240145","DOI":"10.1080\/16078454.2023.2240145","volume":"28","author":"F Han","year":"2023","unstructured":"Han F, Sheng N, Sheng C, Meng J. The diagnostic and prognostic value of haematologic parameters in multiple myeloma patients. Hematology. 2023;28:2240145. https:\/\/doi.org\/10.1080\/16078454.2023.2240145.","journal-title":"Hematology"},{"key":"7830_CR13","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood.2022017863","volume":"141","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S, et al. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. Blood. 2023;141:1308\u201315. https:\/\/doi.org\/10.1182\/blood.2022017863.","journal-title":"Blood"},{"key":"7830_CR14","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of [18F]FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(17)30189-4.","journal-title":"Lancet Oncol"},{"key":"7830_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.20.00386","volume":"39","author":"E Zamagni","year":"2021","unstructured":"Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, et al. Standardization of [18F]FDG-PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39:116\u201325. https:\/\/doi.org\/10.1200\/JCO.20.00386.","journal-title":"J Clin Oncol"},{"key":"7830_CR16","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00259-019-4275-5","volume":"46","author":"Y Abe","year":"2019","unstructured":"Abe Y, Narita K, Kobayashi H, Kitadate A, Miura D, Takeuchi M, et al. Pretreatment [18F]FDG PET\/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46:1325\u201333. https:\/\/doi.org\/10.1007\/s00259-019-4275-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7830_CR17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/bjh.14827","volume":"178","author":"A Chantry","year":"2017","unstructured":"Chantry A, Kazmi M, Barrington S, Goh V, Mulholland N, Streetly M, Lai M, Pratt G. British Society for Haematology Guidelines. Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol. 2017;178:380\u201393. https:\/\/doi.org\/10.1111\/bjh.14827.","journal-title":"Br J Haematol"},{"key":"7830_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12149-022-01812-x","volume":"37","author":"B Wan","year":"2023","unstructured":"Wan B, Zhang S, Wang P, Deng P, Dai W. Prognostic value of semi-quantitative parameters of [18F]FDG PET\/CT in newly diagnosed multiple myeloma patients. Ann Nucl Med. 2023;37:155\u201365. https:\/\/doi.org\/10.1007\/s12149-022-01812-x.","journal-title":"Ann Nucl Med"},{"key":"7830_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/bjh.16633","volume":"191","author":"T Terao","year":"2020","unstructured":"Terao T, Machida Y, Tsushima T, Miura D, arita K, Kitadate A, et al. Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography\/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice. Br J Haematol. 2020;191:223\u201330. https:\/\/doi.org\/10.1111\/bjh.16633.","journal-title":"Br J Haematol"},{"key":"7830_CR20","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","volume":"53","author":"R Fonti","year":"2012","unstructured":"Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, et al. Metabolic tumor volume assessed by [18F]FDG PET\/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53:1829\u201335. https:\/\/doi.org\/10.2967\/jnumed.112.106500.","journal-title":"J Nucl Med"},{"key":"7830_CR21","doi-asserted-by":"publisher","first-page":"671904","DOI":"10.3389\/fimmu.2021.671904","volume":"12","author":"J Cui","year":"2021","unstructured":"Cui J, Zou Z, Duan J, Tang W, Li Y, Zhang L, et al. Predictive Values of PET\/CT in combination with regulatory B cells for therapeutic response and survival in contemporary patients with newly diagnosed multiple myeloma. Front Immunol. 2021;12:671904. https:\/\/doi.org\/10.3389\/fimmu.2021.671904.","journal-title":"Front Immunol"},{"key":"7830_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00277-019-03852-2","volume":"99","author":"R Fonti","year":"2020","unstructured":"Fonti R, Pellegrino S, Catalano L, Pane F, Del Vecchio S, Pace L. Visual and volumetric parameters by [18F]FDG-PET\/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma. Ann Hematol. 2020;99:127\u201335. https:\/\/doi.org\/10.1007\/s00277-019-03852-2.","journal-title":"Ann Hematol"},{"key":"7830_CR23","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n7","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n7.","journal-title":"BMJ"},{"key":"7830_CR24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","volume":"158","author":"JA Hayden","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, C\u00f4t\u00e9 P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158:280\u20136. https:\/\/doi.org\/10.7326\/0003-4819-158-4-201302190-00009.","journal-title":"Ann Intern Med"},{"key":"7830_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"7830_CR26","doi-asserted-by":"publisher","first-page":"e15987","DOI":"10.1097\/MD.0000000000015987","volume":"98","author":"L Shi","year":"2019","unstructured":"Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Med (Baltim). 2019;98:e15987. https:\/\/doi.org\/10.1097\/MD.0000000000015987.","journal-title":"Med (Baltim)"},{"key":"7830_CR27","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/ajh.25279","volume":"93","author":"MA Aljama","year":"2018","unstructured":"Aljama MA, Sidiqi MH, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, et al. Utility and prognostic value of [18F]FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. Am J Hematol. 2018;93:1518\u201323. https:\/\/doi.org\/10.1002\/ajh.25279.","journal-title":"Am J Hematol"},{"key":"7830_CR28","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, et al. [18F]fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068\u201376. https:\/\/doi.org\/10.1182\/blood-2009-03-213280.","journal-title":"Blood"},{"key":"7830_CR29","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1182\/bloodadvances.2022007052","volume":"6","author":"C Charalampous","year":"2022","unstructured":"Charalampous C, Goel U, Broski SM, Dingli D, Kapoor P, Gertz MA, et al. Utility of PET\/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Adv. 2022;6:2763\u201372. https:\/\/doi.org\/10.1182\/bloodadvances.2022007052.","journal-title":"Blood Adv"},{"key":"7830_CR30","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41408-021-00577-2","volume":"11","author":"HJ Cho","year":"2021","unstructured":"Cho HJ, Jung SH, Jo JC, Lee YJ, Yoon SE, Park SS, et al. Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and [18F]FDG PET\/CT. Blood Cancer J. 2021;11:190. https:\/\/doi.org\/10.1038\/s41408-021-00577-2.","journal-title":"Blood Cancer J"},{"key":"7830_CR31","doi-asserted-by":"publisher","first-page":"4198673","DOI":"10.1155\/2018\/4198673","volume":"2018","author":"S Deng","year":"2018","unstructured":"Deng S, Zhang B, Zhou Y, Xu X, Li J, Sang S, et al. The role of [18F]FDG PET\/CT in multiple myeloma staging according to IMPeTUs: comparison of the Durie-Salmon plus and other staging systems. Contrast Media Mol Imaging. 2018;2018:4198673. https:\/\/doi.org\/10.1155\/2018\/4198673.","journal-title":"Contrast Media Mol Imaging"},{"key":"7830_CR32","doi-asserted-by":"publisher","first-page":"668099","DOI":"10.3389\/fonc.2021.668099","volume":"11","author":"J He","year":"2021","unstructured":"He J, Yue X, He D, Zhao Y, Yang Y, Zheng G, et al. Multiple extramedullary-bone related and\/or extramedullary extraosseous are independent poor prognostic factors in patients with newly diagnosed multiple myeloma. Front Oncol. 2021;11:668099. https:\/\/doi.org\/10.3389\/fonc.2021.668099.","journal-title":"Front Oncol"},{"key":"7830_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00259-018-4114-0","volume":"46","author":"SH Jung","year":"2019","unstructured":"Jung SH, Kwon SY, Min JJ, Bom HS, Ahn SY, Jung SY, et al. [18F]FDG PET\/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. Eur J Nucl Med Mol Imaging. 2019;46:107\u201315. https:\/\/doi.org\/10.1007\/s00259-018-4114-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7830_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40644-023-00625-z","volume":"23","author":"H Lee","year":"2023","unstructured":"Lee H, Hyun SH, Cho YS, Moon SH, Choi JY, Kim K, et al. Semi-quantitative FDG parameters predict survival in multiple myeloma patients without autologous stem cell transplantation. Cancer Imaging. 2023;23:104. https:\/\/doi.org\/10.1186\/s40644-023-00625-z.","journal-title":"Cancer Imaging"},{"key":"7830_CR35","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s00259-022-06088-x","volume":"50","author":"J Li","year":"2023","unstructured":"Li J, Zhang X, Qin C, Sun X, Xu X, Cao G, et al. A prognostication system based on clinical parameters and [18F]FDG PET\/CT in patients with newly diagnosed multiple myeloma. Eur J Nucl Med Mol Imaging. 2023;50:1665\u201370. https:\/\/doi.org\/10.1007\/s00259-022-06088-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7830_CR36","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1007\/s00277-021-04629-2","volume":"100","author":"J Li","year":"2021","unstructured":"Li J, Tan H, Xu T, Shi H, Liu P. Bone marrow tracer uptake pattern of PET-CT in multiple myeloma: image interpretation and prognostic value. Ann Hematol. 2021;100:2979\u201388. https:\/\/doi.org\/10.1007\/s00277-021-04629-2.","journal-title":"Ann Hematol"},{"key":"7830_CR37","doi-asserted-by":"publisher","first-page":"9895","DOI":"10.3390\/ijms23179895","volume":"23","author":"MI Morales-Lozano","year":"2022","unstructured":"Morales-Lozano MI, Rodriguez-Otero P, Sancho L, Nu\u00f1ez-Cordoba JM, Prieto E, Marcos-Jubilar M, et al. 11C-Methionine PET\/CT in assessment of multiple myeloma patients: comparison to [18F]FDG PET\/CT and prognostic value. Int J Mol Sci. 2022;23:9895. https:\/\/doi.org\/10.3390\/ijms23179895.","journal-title":"Int J Mol Sci"},{"key":"7830_CR38","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.3390\/cancers13081938","volume":"13","author":"C Mesguich","year":"2021","unstructured":"Mesguich C, Latrabe V, Hulin C, Lascaux A, Bordenave L, Hindi\u00e9 E, et al. Prospective vomparison of [18F]FDG PET\/CT and whole-body MRI with diffusion-weighted imaging in the evaluation of treatment response of multiple myeloma patients eligible for autologous stem cell transplant. Cancers (Basel). 2021;13:1938. https:\/\/doi.org\/10.3390\/cancers13081938.","journal-title":"Cancers (Basel)"},{"key":"7830_CR39","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.3390\/cancers12092532","volume":"12","author":"AV Michaud-Robert","year":"2020","unstructured":"Michaud-Robert AV, Zamagni E, Carlier T, Bailly C, Jamet B, Touzeau C, et al. Glucose metabolism quantified by SUVmax on baseline FDG-PET\/CT predicts survival in newly diagnosed multiple myeloma patients: combined harmonized analysis of two prospective phase III trials. Cancers (Basel). 2020;12:2532. https:\/\/doi.org\/10.3390\/cancers12092532.","journal-title":"Cancers (Basel)"},{"key":"7830_CR40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3348\/kjr.2018.19.3.481","volume":"19","author":"SH Moon","year":"2018","unstructured":"Moon SH, Choi WH, Yoo IR, Lee SJ, Paeng JC, Jeong SY, et al. Prognostic value of baseline [18F]fluorodeoxyglucose PET\/CT in patients with multiple myeloma: a multicenter cohort study. Korean J Radiol. 2018;19:481\u20138. https:\/\/doi.org\/10.3348\/kjr.2018.19.3.481.","journal-title":"Korean J Radiol"},{"key":"7830_CR41","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM Study. J Clin Oncol. 2017;35:2911\u20138. https:\/\/doi.org\/10.1200\/JCO.2017.72.2975.","journal-title":"J Clin Oncol"},{"key":"7830_CR42","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00259-024-06668-z","volume":"51","author":"C Sachpekidis","year":"2024","unstructured":"Sachpekidis C, Enqvist O, Ul\u00e9n J, Kopp-Schneider A, Pan L, Mai EK, et al. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET\/CT predicts survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2024;51:2293\u2013307. https:\/\/doi.org\/10.1007\/s00259-024-06668-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7830_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13550-021-00846-y","volume":"11","author":"C Sachpekidis","year":"2021","unstructured":"Sachpekidis C, Merz M, Raab MS, Bertsch U, Weru V, Schneider AK, et al. The prognostic signifcance of [18F]FDG PET\/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Res. 2021;11:100. https:\/\/doi.org\/10.1186\/s13550-021-00846-y.","journal-title":"EJNMMI Res"},{"key":"7830_CR44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/ejh.13006","volume":"100","author":"H Tu","year":"2018","unstructured":"Tu H, He Y, Huang T, Choe S, Lan X, Duan X, et al. Predictive value of [18F] FDG PET\/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma. Eur J Haematol. 2018;100:189\u201397. https:\/\/doi.org\/10.1111\/ejh.13006.","journal-title":"Eur J Haematol"},{"key":"7830_CR45","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of [18F] FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989\u201395. https:\/\/doi.org\/10.1182\/blood-2011-06-361386.","journal-title":"Blood"},{"key":"7830_CR46","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","volume":"21","author":"E Zamagni","year":"2015","unstructured":"Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L, et al. PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res. 2015;21:4384\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0396.","journal-title":"Clin Cancer Res"},{"key":"7830_CR47","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.2967\/jnumed.121.262884","volume":"63","author":"JB Alberge","year":"2022","unstructured":"Alberge JB, Kraeber-Bod\u00e9r\u00e9 F, Jamet B, Touzeau C, Caillon H, Wuilleme S, et al. Molecular signature of [18F]FDG PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET Study. J Nucl Med. 2022;63:1008\u201313. https:\/\/doi.org\/10.2967\/jnumed.121.262884.","journal-title":"J Nucl Med"},{"key":"7830_CR48","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","volume":"46","author":"Y Abe","year":"2019","unstructured":"Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D, et al. Low hexokinase-2 expression-associated false-negative [18F]FDG PET\/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46:1345\u201350. https:\/\/doi.org\/10.1007\/s00259-019-04312-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7830_CR49","doi-asserted-by":"publisher","first-page":"22188","DOI":"10.1038\/s41598-021-01740-2","volume":"11","author":"M Chen","year":"2021","unstructured":"Chen M, Zhu W, Du J, Yang C, Han B, et al. [11C] acetate positron emission tomography is more precise than [18F]fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma. Sci Rep. 2021;11:22188. https:\/\/doi.org\/10.1038\/s41598-021-01740-2.","journal-title":"Sci Rep"},{"key":"7830_CR50","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/RLU.0000000000000696","volume":"40","author":"R Fonti","year":"2015","unstructured":"Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, et al. [18F]FDG PET\/CT, [99mTc] MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study. Clin Nucl Med. 2015;40:303\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000000696.","journal-title":"Clin Nucl Med"},{"key":"7830_CR51","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00259-020-05078-1","volume":"48","author":"A Paschali","year":"2021","unstructured":"Paschali A, Panagiotidis E, Triantafyllou T, Palaska V, Tsirou K, Verrou E, et al. A proposed index of diffuse bone marrow [18F]FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy. Eur J Nucl Med Mol Imaging. 2021;48:1487\u201397. https:\/\/doi.org\/10.1007\/s00259-020-05078-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7830_CR52","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/MNM.0000000000000610","volume":"38","author":"K Sonmezoglu","year":"2017","unstructured":"Sonmezoglu K, Vatankulu B, Elverdi T, Akyel R, Erkan ME, Halac M, et al. The role of [68Ga] DOTA-TATE PET\/CT scanning in the evaluation of patients with multiple myeloma: preliminary results. Nucl Med Commun. 2017;38:76\u201383. https:\/\/doi.org\/10.1097\/MNM.0000000000000610.","journal-title":"Nucl Med Commun"},{"key":"7830_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/RLU.0b013e3181c3619c","volume":"35","author":"M Castellani","year":"2010","unstructured":"Castellani M, Carletto M, Baldini L, Calori R, Longari V, Soligo D, et al. The prognostic value of [18F] fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with [99mTc] sestamibi. Clin Nucl Med. 2010;35:1\u20135. https:\/\/doi.org\/10.1097\/RLU.0b013e3181c3619c.","journal-title":"Clin Nucl Med"},{"key":"7830_CR54","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1007\/s00259-024-06621-0","volume":"51","author":"Z Chen","year":"2024","unstructured":"Chen Z, Yang A, Chen A, Dong J, Lin J, Huang C, et al. [68Ga] Pentixafor PET\/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2024;51:1926\u201336. https:\/\/doi.org\/10.1007\/s00259-024-06621-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7830_CR55","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4999\/uhod.236546","volume":"1","author":"D Ozbalci","year":"2023","unstructured":"Ozbalci D, Erdogan M, Guchan-Alanoglu E, Sengul SS, Bacak, Burcu, et al. PET-CT guided adipose tissue indices as prognostic factors in multiple myeloma. Int J Hematol Oncol. 2023;1:33. https:\/\/doi.org\/10.4999\/uhod.236546.","journal-title":"Int J Hematol Oncol"},{"key":"7830_CR56","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s00259-011-1738-8","volume":"38","author":"R Haznedar","year":"2011","unstructured":"Haznedar R, Ak\u0131 SZ, Akdemir OU, Ozkurt ZN, Ceneli O, Ya\u011fc\u0131 M, et al. Value of [18F]fluorodeoxyglucose uptake in positron emission tomography\/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38:1046\u201353. https:\/\/doi.org\/10.1007\/s00259-011-1738-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7830_CR57","doi-asserted-by":"publisher","first-page":"407584","DOI":"10.1016\/j.clnu.2021.02.010","volume":"40","author":"AD da Cunha J\u00fanior","year":"2021","unstructured":"da Cunha J\u00fanior AD, Silveira MN, Takahashi MES, de Souza EM, Mosci C, Ramos CD, et al. Visceral adipose tissue glucose uptake is linked to prognosis in multiple myeloma patients: An exploratory study. Clin Nutr. 2021;40:407584. https:\/\/doi.org\/10.1016\/j.clnu.2021.02.010.","journal-title":"Clin Nutr"},{"key":"7830_CR58","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13550-024-01113-6","volume":"14","author":"S Marchiori","year":"2024","unstructured":"Marchiori S, Cousin F, Papadopoulos I, Bernard C, Thys M, De Prijck B, et al. Prognostic value of visual IMPeTUs criteria and metabolic tumor burden at baseline [18F]FDG PET\/CT in patients with newly diagnosed multiple myeloma. EJNMMI Res. 2024;14:51. https:\/\/doi.org\/10.1186\/s13550-024-01113-6.","journal-title":"EJNMMI Res"},{"key":"7830_CR59","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1007\/s00277-024-05905-7","volume":"103","author":"S Pellegrino","year":"2024","unstructured":"Pellegrino S, Origlia D, Di Donna E, Lamagna M, Della Pepa R, Pane F, et al. Coefficient of variation and texture analysis of [18F]FDG PET\/CT images for the prediction of outcome in patients with multiple myeloma. Ann Hematol. 2024;103:3713\u201321. https:\/\/doi.org\/10.1007\/s00277-024-05905-7.","journal-title":"Ann Hematol"},{"key":"7830_CR60","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/cancers12051335","volume":"12","author":"C Sachpekidis","year":"2020","unstructured":"Sachpekidis C, Kopp-Schneider A, Merz M, Jauch A, Raab MS, Goldschmidt H, et al. Can [18F] NaF PET\/CT before autologous Stem cell transplantation predict survival in multiple myeloma Cancers. (Basel). 2020;12:1335. https:\/\/doi.org\/10.3390\/cancers12051335.","journal-title":"(Basel)"},{"key":"7830_CR61","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.21037\/qims-21-85","volume":"11","author":"Y Silva","year":"2021","unstructured":"Silva Y, Riedinger JM, Chr\u00e9tien ML, Caillot D, Corre J, Guillen K, et al. Comparison between tumour metabolism derived from [18F]FDG PET\/CT and accurate cytogenetic stratification in newly diagnosed multiple myeloma patients. Quant Imaging Med Surg. 2021;11:4299\u2013309. https:\/\/doi.org\/10.21037\/qims-21-85.","journal-title":"Quant Imaging Med Surg"},{"key":"7830_CR62","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1002\/cam4.5228","volume":"12","author":"W Tang","year":"2023","unstructured":"Tang W, Li Y, Zou Z, Cui J, Wang F, Zheng Y, et al. A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma. Cancer Med. 2023;12:3054\u201367. https:\/\/doi.org\/10.1002\/cam4.5228.","journal-title":"Cancer Med"},{"key":"7830_CR63","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/RLU.0000000000003773","volume":"46","author":"T Terao","year":"2021","unstructured":"Terao T, Machida Y, Hirata K, Kuzume A, Tabata R, Tsushima T, et al. Prognostic impact of metabolic heterogeneity in patients with newly diagnosed multiple myeloma using [18F]FDG PET\/CT. Clin Nucl Med. 2021;46:790\u20136. https:\/\/doi.org\/10.1097\/RLU.0000000000003773.","journal-title":"Clin Nucl Med"},{"key":"7830_CR64","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","volume":"121","author":"SZ Usmani","year":"2013","unstructured":"Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121:1819\u201323. https:\/\/doi.org\/10.1182\/blood-2012-08-451690.","journal-title":"Blood"},{"key":"7830_CR65","doi-asserted-by":"publisher","first-page":"7881","DOI":"10.1038\/s41598-023-34653-3","volume":"13","author":"H Lee","year":"2023","unstructured":"Lee H, Hyun SH, Cho YS, Moon SH, Choi JY, Kim K, et al. Cluster analysis of autoencoder-extracted FDG PET\/CT features identifies multiple myeloma patients with poor prognosis. Sci Rep. 2023;13:7881. https:\/\/doi.org\/10.1038\/s41598-023-34653-3.","journal-title":"Sci Rep"},{"key":"7830_CR66","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1158\/1078-0432.CCR-16-0235","volume":"23","author":"JE McDonald","year":"2017","unstructured":"McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, et al. Assessment of total lesion glycolysis by [18F]FDG PET\/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res. 2017;23:1981\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0235.","journal-title":"Clin Cancer Res"},{"key":"7830_CR67","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","volume":"103","author":"FE Davies","year":"2018","unstructured":"Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, et al. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018;103:1047\u201353. https:\/\/doi.org\/10.3324\/haematol.2017.177139.","journal-title":"Haematologica"},{"key":"7830_CR68","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4103\/ijnm.ijnm_131_24","volume":"39","author":"TA Kirkizlar","year":"2024","unstructured":"Kirkizlar TA, Kirkizlar O, Soyluoglu S, Umit EG, Ustun F, Demir AM. The Impact of focal lesions on overall and progression-free survival in multiple myeloma. Indian J Nucl Med. 2024;39:353\u20139. https:\/\/doi.org\/10.4103\/ijnm.ijnm_131_24.","journal-title":"Indian J Nucl Med"},{"key":"7830_CR69","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.3390\/jcm12062280","volume":"12","author":"B Ni","year":"2023","unstructured":"Ni B, Huang G, Huang H, Wang T, Han X, Shen L, et al. Machine learning model based on optimized radiomics feature from [18F] FDG-PET\/CT and clinical characteristics predicts prognosis of multiple myeloma: a preliminary study. J Clin Med. 2023;12:2280. https:\/\/doi.org\/10.3390\/jcm12062280.","journal-title":"J Clin Med"},{"key":"7830_CR70","doi-asserted-by":"publisher","first-page":"918","DOI":"10.2214\/AJR.19.21283","volume":"213","author":"Y Abe","year":"2019","unstructured":"Abe Y, Narita K, Kobayashi H, Kitadate A, Takeuchi M, O\u2019uchi T, et al. Medullary abnormalities in appendicular skeletons detected with [18F]FDG PET\/CT predict an unfavorable prognosis in newly diagnosed multiple myeloma patients with high-risk factors. AJR Am J Roentgenol. 2019;213:918\u201324. https:\/\/doi.org\/10.2214\/AJR.19.21283.","journal-title":"AJR Am J Roentgenol"},{"key":"7830_CR71","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ajh.25507","volume":"94","author":"R Alonso","year":"2019","unstructured":"Alonso R, Cedena MT, G\u00f3mez-Grande A, R\u00edos R, Moraleda JM, Caba\u00f1as V, et al. Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. Am J Hematol. 2019;94:853\u201361. https:\/\/doi.org\/10.1002\/ajh.25507.","journal-title":"Am J Hematol"},{"key":"7830_CR72","doi-asserted-by":"publisher","first-page":"936993","DOI":"10.3389\/fonc.2022.936993","volume":"12","author":"A Oliver-Caldes","year":"2022","unstructured":"Oliver-Caldes A, Soler-Perromat JC, Lozano E, Moreno D, Bataller A, Mozas P, et al. Long-term responders after autologous stem cell transplantation in multiple myeloma. Front Oncol. 2022;12:936993. https:\/\/doi.org\/10.3389\/fonc.2022.936993.","journal-title":"Front Oncol"},{"key":"7830_CR73","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00259-020-05049-6","volume":"48","author":"B Jamet","year":"2021","unstructured":"Jamet B, Morvan L, Nanni C, Michaud AV, Bailly C, Chauvie S, et al. Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. Eur J Nucl Med Mol Imaging. 2021;48:1005\u201315. https:\/\/doi.org\/10.1007\/s00259-020-05049-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7830_CR74","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12880-023-01033-2","volume":"23","author":"H Zhong","year":"2023","unstructured":"Zhong H, Huang D, Wu J, Chen X, Chen Y, Huang C. [18F]FDG PET\/CT based radiomics features improve prediction of prognosis: multiple machine learning algorithms and multimodality applications for multiple myeloma. BMC Med Imaging. 2023;23:87. https:\/\/doi.org\/10.1186\/s12880-023-01033-2.","journal-title":"BMC Med Imaging"},{"key":"7830_CR75","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.clml.2013.07.003","volume":"13","author":"R Bataille","year":"2013","unstructured":"Bataille R, Annweiler C, Beauchet O. Multiple myeloma international staging system: staging or simply aging system. Clin Lymphoma Myeloma Leuk. 2013;13:635\u20137. https:\/\/doi.org\/10.1016\/j.clml.2013.07.003.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7830_CR76","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s43657-023-00108-y","volume":"3","author":"Y Li","year":"2023","unstructured":"Li Y, Li F, Han S, Ning J, Su P, Liu J, et al. Performance of [18F] DCFPyL PET\/CT in primary prostate cancer diagnosis, gleason grading and d\u2019amico classification: a radiomics-based study. Phenomics. 2023;3:576\u201385. https:\/\/doi.org\/10.1007\/s43657-023-00108-y.","journal-title":"Phenomics"},{"key":"7830_CR77","doi-asserted-by":"publisher","unstructured":"Dong J, Huang K, Lai S, Peng Y, Liu Y, Li X et al. Novel Imaging Technology for Biomedical and Clinical Application. Phenomics. 2025. https:\/\/doi.org\/10.1007\/s43657-024-00167-9","DOI":"10.1007\/s43657-024-00167-9"},{"issue":"suppl4","key":"7830_CR78","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl4):iv52\u201361. https:\/\/doi.org\/10.1093\/annonc\/mdx096.","journal-title":"Ann Oncol"},{"key":"7830_CR79","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10238-021-00775-z","volume":"23","author":"Q Li","year":"2023","unstructured":"Li Q, Hu L, Charwudzi A, Zhu W, Meng Y, Zhai Z. Prognostic value of [18F]fluorodeoxyglucose positron emission tomography\/computed tomography at diagnosis in untreated multiple myeloma patients: a systematic review and meta-analysis. Clin Exp Med. 2023;23:31\u201343. https:\/\/doi.org\/10.1007\/s10238-021-00775-z.","journal-title":"Clin Exp Med"},{"key":"7830_CR80","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00330-020-07177-x","volume":"31","author":"S Han","year":"2021","unstructured":"Han S, Woo S, Kim YI, Yoon DH, Ryu JS. Prognostic value of [18F]fluorodeoxyglucose positron emission tomography\/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis. Eur Radiol. 2021;31:152\u201362. https:\/\/doi.org\/10.1007\/s00330-020-07177-x.","journal-title":"Eur Radiol"},{"key":"7830_CR81","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2967\/jnumed.106.035774","volume":"48","author":"M Soret","year":"2007","unstructured":"Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932\u201345. https:\/\/doi.org\/10.2967\/jnumed.106.035774.","journal-title":"J Nucl Med"},{"key":"7830_CR82","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00259-013-2391-1","volume":"40","author":"C Lasnon","year":"2013","unstructured":"Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, Aide N. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40:985\u201396. https:\/\/doi.org\/10.1007\/s00259-013-2391-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7830_CR83","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1097\/RLU.0000000000005731","volume":"50","author":"H Kaur","year":"2025","unstructured":"Kaur H, Kumar S, Watts A, Singh C, Sachdeva MUS, Sreedharanunni S, et al. [68Ga]Pentixafor PET\/CT-Based Response Evaluation and its Prognostic Value in Multiple Myeloma: Comparison With IMWG and [18F]FDG-Based Response. Clin Nucl Med. 2025;50:e331\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000005731.","journal-title":"Clin Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07830-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07830-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07830-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:20:44Z","timestamp":1780996844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07830-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":83,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7830"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07830-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a systematic literature review and therefore no ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"All authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}